Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE WAS VALUED AT USD 1.93 BILLION IN 2021 AND IS EXPECTED TO REACH USD 5.10 BILLION BY 2027, GROWING AT A CAGR OF 17.59% DURING THE FORECAST PERIOD.
The Global Virtual Clinical Trials Market Size, Share, Growth Forecast by:
- Study Type: Interventional and Others
- Phases: Late Stage and Early Stage
- Therapeutic Area: Oncology, Rare & Genetic Diseases, CNS, Immunology, and Other
- Company Size: Small & Mid-Sized and Large Sized
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share, & Forecast 2022-2027
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
VIRTUAL CLINICAL TRIALS MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2027) | USD 5.10 Billion |
| Market Size (2021) | USD 1.93 Billion |
| CAGR (2022-2027) | 17.59% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Study Type, Phases, Therapeutic Area, Company Size, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY VENDORS | Dassault Systèmes, Medable, Science 37, and THREAD |
The global virtual clinical trials market is expected to reach USD 5.10 billion by 2027 from USD 1.93 billion in 2021, growing with a CAGR of 17.59% from 2022-2027. The virtual clinical trials market is one of the innovative approaches for traditional clinical trials, through remote monitoring and more patient-centric approaches. These virtual clinical trials adoption was high during the COVID-19 pandemic period and the usage of decentralized clinical trials components application rate. Most clinical trial conductors started to move towards the decentralized or hybrid clinical trial model.
Virtual clinical trials are also known as de-centralized clinical trials. Although the vendors adopted virtual clinical trials for many years, however, it was very slow adoption before the pandemic. The virtual clinical trials market includes the application of digital tools and technological processes that take trials from healthcare settings to patients’ homes or places of work. The reduction in site visits, associated time, and economic cost cuttings eliminate the burden placed on patients and solve the challenges for trial participation. The virtual clinical trials market brought significant advantages and reduced major challenges like patient retention, recruitment, and more. These are the factors that fuel market growth.
MARKET TRENDS
Virtual clinical trials are an alternative method to traditional clinical trial methods. The new connected devices power clinical trial activities with better clinical data collection, analysis, and interpretations play a significant role. Clinical trial monitoring devices, clinical trial software, eCOA & ePRO, and eConsent are some digital tools that strengthen clinical trial activities and give a new shift in the clinical trial industry. On another side, the bring-your-own-devices strategy, a newly adopted trend, is widely accepted among CROs and sponsors. This new strategy allows the trial participants to deliver required data with their own internet-enabled solutions. Technological advances and confidence in improved study outcomes can bring new solutions.
The latest retrospective approach, adopting the synthetic clinical trial approach, delivers significant clinical development. Many biopharma and medical device companies face challenges in finding participants for clinical trials; this synthetic arm process is one of the easy methods, using the innovative approach for collecting and comparing data called the synthetic control arm. This is one of the fully new approaches in the virtual clinical trials market and is expected to drive significant growth. In addition, the involvement of Artificial Intelligence (AI) in clinical trials significantly changes the trial procedure as AI can expedite target validation, clinical trial design, and patient identification for participation in virtual clinical trials.
INDUSTRY DRIVERS
The COVID-19 pandemic is the significant factor that shifted the traditional clinical trials approach to the virtual clinical trials market. The rapid surge of COVID-19 infections poses substantial challenges in the clinical trial space, where the virtual clinical trial model significantly pushed the biopharmaceutical and medical device industry towards decentralization (DCT). During the COVID-19 pandemic period, approximately 87% of clinical trial sponsors and contract research organizations decentralized the clinical trial activities compared with 28% only pre-covid period.
The market players and the companies pioneer in clinical trials activities understand that decentralization in clinical trials is the future of the clinical trials space. Over the last few years, decentralization has rapidly grown in the clinical trials industry. Decentralization of clinical trials has significant potential since the virtual clinical trials are independent of regional/geographical locations and are implemented through digital health platforms as well as mobile and local healthcare segments; this makes the providers eliminate the constraints associated with the traditional model.
Regulatory changes in favor of DCT: The pandemic period (COVID-19 Crisis) has supercharged the changes for virtual clinical trials from regulatory agencies worldwide. Including Food Drugs Administration (FDA), UK’s Medicine and Healthcare Product Regulatory Agency (MHRA), European Medicine Agency (EMA), China’s Center for Drug Evaluation (CDE), and Singapore Health Science Authority (HSA) have made revolutionary regulations towards the virtual clinical trials market.
On another side, the challenges associated with the virtual clinical trials model, such as the high expenditure required for the initial implementation, data reliability and integrity, and varied state law and regulations, are some factors that hamper the market growth. In addition, the increasing digital tools and growing risk of cyber-attacks are challenging aspects of the virtual clinical trials market growth.
SEGMENTATION ANALYSIS
INSIGHTS BY STUDY TYPE
The global virtual clinical trials market by study type is segmented into interventional and others. The interventional study type segment accounts for an 80.15% higher market share and dominates other segments. The increasing R&D activities in the medical industry led to increased clinical trials. In interventional study type, the growing application of a digital tool for clinical trial data collection and analysis gives high demand for virtual clinical trials platform that increases the segmental growth. Also, with the increasing infection rate of SARS-COV-2, a higher number of clinical trials for vaccine development registered in the period 2020 to 2022, which has increased the adoption of virtual tools in clinical trials.
INSIGHTS BY STAGE OF DEVELOPMENT
The early and late phases are two primary segments under the stage of development in the global virtual clinical trials market. The early phase segment accounted for 41.55% market share, and the late phase segment accounted for 58.45% market share in 2021. The high number of clinical trials are currently accounted for the phase III & phase IV, which is increasing the adoption of DCT platforms for data accuracy and better outcomes. As well as increasing adoption of DCT platforms and tools in phase, I & phase II trial procedures for patient participation will drive the market growth of the early phase segment in 2021.
INSIGHTS BY THERAPY AREA
The global virtual clinical trials market is segmented into cancer, CVD, infectious diseases, gastroenterology disorders, musculoskeletal diseases, nervous system, and other indications by therapy area. The oncology segment accounted for 44.85% higher market share in the virtual clinical trials market in 2021 and dominated all other segments. The de-centralized clinical trials are majorly accounted for oncology therapeutic areas. More home-based clinical trials are adopted in the diseases segment. This is more patient-centric and helps them provide better clinical outcomes to the clinical trial sponsors. Most of the major market players also show the major de-centralized clinical trials are associated with cancer indications. In 2020, the oncology therapeutic area showed more than 22% for adopting de-centralized clinical trials.
The rare and genetic diseases segment is second, accounting for 15.54% of the market share. Increasing prevalence and constantly addressing rare new diseases and genetic diseases drive the high demand for clinical research. Rare and genetic disorders are one of the major challenging segments in traditional clinical trials segment. This is easily overcome using virtual clinical trials, especially in patient recruitment, retention, and more. Globally more than 6,000 rare diseases the time addressed. It might be increasing in the upcoming time, which will drive the demand for clinical research activities; the increasing prevalence of genetic diseases and rare diseases are the factors that drive the demand for de-centralized clinical trial adoption.
GEOGRAPHICAL LANDSCAPE
North America is the leading region in the global virtual clinical trials market, accounting for 53.54% market share. The increasing clinical trial activities, well-established and advanced clinical trial infrastructure, and adoption of decentralization in clinical trials over the last decades have driven the high market growth in the North American region. Behind North America, Europe is one of the leading regions for virtual clinical trials. The increased acceptance of digital and more connected technologies, the high patient population, and increasing awareness among clinical trial investigators, sponsors, and contract research organizations about virtual clinical trials drive the market growth in the region. In addition, larger geographical landmass and limited healthcare settings make virtual clinical trials an ideal solution for Europe.
APAC is still in the infant stage of adopting virtual clinical trials, but it has vast opportunities to deliver to the virtual clinical trials market. In recent years, clinical trial activities in APAC countries significantly increased. Currently, APAC is well known for its clinical trial industry hub. Large patient populations, diverse ethnicities & geographies, treatment demanding populations, similar diseases pattern, increasing technology adoption in clinical trials, and rapidly growing biopharma industries are some key elements that accelerate virtual clinical trials market growth.
VENDOR LANDSCAPE
Medable, Science 37, THREAD, Dassault Systèmes (Medidata), IQVIA, Clinical ink, Castor, ObvioHealth, Labcorp Drug Development, ERT, Signant Health, Covance, Jeeva, Accenture, and Delve Health are some of the significant players in the global virtual clinical trials market. Further, factors such as increasing drug development focused by various big pharma and biotech companies, continuously increasing their expenditure on research and development activities, clinical trials, and development of advanced solutions triggered high competency in the biopharmaceutical industry. Increasing competition in the pharma industry directly impacts the competitiveness in the virtual clinical trial market.
THREAD offers a unique, innovative, and highly advanced decentralized clinical trial platform in the virtual clinical trials market. THREAD is a fully configurable and singular DCT platform with services that deliver global scalability and rapid flexibility from DCT study design. In 2022, the company acquired inVibe to ingrate the voice of the trial participants and broaden the trial design and research capabilities.
Frequently Asked Questions
What is the size of the global virtual clinical trials market?
What is the global virtual clinical trials market growth?
What are the trends in the global virtual clinical trials market?
Who are the key players in the global virtual clinical trials market?
Which region will dominate the global virtual clinical trials market share?
The global virtual clinical trials market is expected to grow at a CAGR of approximately 17.59% from 2022 to 2027.
The following factors are likely to contribute to the growth of the global virtual clinical trials market during the forecast period:
- Covid-19 Accelerate the Virtual Clinical Trials Adoption
- Decentralization of Clinical Trials is a Future of Clinical Trials
- Regulatory Changes in Favour of Virtual Clinical Trials
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the global virtual clinical trials market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Vendors
Key Company Profiles
- Dassault Systèmes
- Business Overview
- Product Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- Medable
- Science 37
- THREAD
Key Companies To Watch
- Accenture
- Castor
- Clinical ink
- Clario
- Delve Health
- eClinicalHealth
- IQVIA
- Labcorp Drug Development
- ObvioHealth
- Signant Health
- Thermo Fisher Scientific
Other Prominent Vendors
- Advarra
- Business Overview
- Product Offerings
- Curavit Clinical Research
- CMIC Holdings
- Icon Plc
- Jeeva Informatics Solutions
- LEO Innovation Lab
- Oracle
- Paraxel International Corporation
- ProPharma Group
Segmentation by Study Type
- Interventional
- Others
Segmentation by Phases
- Late Stage
- Early Stage
Segmentation by Therapeutic Area
- Oncology
- Rare & Genetic Diseases
- CNS
- Immunology
- Other
Segmentation by Company Size
- Small & Mid-Sized
- Large Sized
Segmentation by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- APAC
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- South Africa
EXHIBIT 1 SEGMENTATION OF GLOBAL VIRTUAL CLINICAL TRIALS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 GLOBAL VIRTUAL CLINICAL TRIALS MARKET SEGMENTATION 2021–2027
EXHIBIT 4 APPLICATION OF E-CLINICAL TOOLS TO MANAGE VIRTUAL CLINICAL TRIALS
EXHIBIT 5 IMPACT OF ADOPTION OF “BRING-YOUR-OWN-DEVICE” STRATEGY
EXHIBIT 6 POTENTIAL STRENGTHS OF BYOD STRATEGY IN VIRTUAL CLINICAL TRIALS
EXHIBIT 7 CLINICAL TRIALS POWERED WITH BETTER DATA THROUGH NEW CONNECTED DEVICES
EXHIBIT 8 NEW CONNECTED DEVICES POWERS CLINICAL TRIALS WITH BETTER DATA
EXHIBIT 9 IMPACT OF ADOPTION OF SYNTHETIC CLINICAL TRIALS
EXHIBIT 10 IMPACT OF SPIKE IN VIRTUAL CLINICAL TRIAL ADOPTION DUE TO COVID-19
EXHIBIT 11 COVID-19 IMPACT ON VIRTUAL CLINICAL TRIAL ADOPTION (BEFORE- DURING-AFTER)
EXHIBIT 12 CHALLENGES ASSOCIATED WITH TRADITIONAL CLINICAL TRIAL METHODS
EXHIBIT 13 IMPACT OF DECENTRALIZATION OF CLINICAL TRIALS
EXHIBIT 14 FACTORS FUELING DECENTRALIZATION IN CLINICAL TRIALS
EXHIBIT 15 IMPACT OF REGULATORY CHANGES IN FAVOR OF VIRTUAL CLINICAL TRIALS
EXHIBIT 16 REGULATION OVERVIEW: DECENTRALIZED CLINICAL COMPONENTS BY COUNTRY
EXHIBIT 17 IMPACT OF CHALLENGES ASSOCIATED WITH VIRTUAL CLINICAL TRIALS
EXHIBIT 18 IMPACT OF COMPLEXITY IN DECENTRALIZED CLINICAL TRIALS
EXHIBIT 19 IMPACT OF INCREASING ALTERNATIVES FOR VIRTUAL CLINICAL TRIALS
EXHIBIT 20 ALTERNATIVE CLINICAL TRIAL MODELS FOR DECENTRALIZED CLINICAL TRIALS
EXHIBIT 21 CLINICAL TRIAL ACTIVITIES BY TRADITIONAL, HYBRID, & FULLY DECENTRALIZED TRIALS 2021
EXHIBIT 22 GLOBAL VIRTUAL CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 23 GLOBAL VIRTUAL CLINICAL TRIALS MARKET SHARE BY STUDY TYPE 2021 &2027
EXHIBIT 24 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY PHASES 2021 &2027
EXHIBIT 25 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY THERAPEUTIC AREA 2021 &2027
EXHIBIT 26 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY GEOGRAPHY 2021 &2027
EXHIBIT 27 FIVE FORCES ANALYSIS 2021
EXHIBIT 28 INCREMENTAL GROWTH BY STUDY TYPE 2021 & 2027
EXHIBIT 29 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY STUDY TYPE 2021–2027
EXHIBIT 30 VIRTUAL CLINICAL TRIALS MARKET BY STUDY DESIGN: INCREMENTAL GROWTH
EXHIBIT 31 VIRTUAL CLINICAL TRIALS MARKET BY STUDY DESIGN: ABSOLUTE GROWTH
EXHIBIT 32 VIRTUAL CLINICAL TRIALS MARKET BY INTERVENTIONAL STUDY: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 33 GLOBAL VIRTUAL CLINICAL INTERVENTIONAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 34 VIRTUAL CLINICAL TRIALS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 35 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY OTHER STUDY TYPE 2021–2027 ($ MILLION)
EXHIBIT 36 INCREMENTAL GROWTH BY PHASES 2021 & 2027
EXHIBIT 37 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY PHASES 2021–2027
EXHIBIT 38 DCT ACTIVITIES BY CLINICAL TRIALS PHASES (2020-2022)
EXHIBIT 39 VIRTUAL CLINICAL TRIALS MARKET BY PHASES: INCREMENTAL GROWTH
EXHIBIT 40 VIRTUAL CLINICAL TRIALS MARKET BY PHASES: ABSOLUTE GROWTH
EXHIBIT 41 TOTAL REGISTERED PHASE III CLINICAL TRIALS 2000–2021
EXHIBIT 42 PHASE III CLINICAL TRIALS 2010–2020
EXHIBIT 43 VIRTUAL LATE STAGE CLINICAL TRIALS MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 44 GLOBAL LATE STAGE VIRTUAL CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 45 GLOBAL PHASE I CLINICAL TRIALS STUDIES 2010-2020
EXHIBIT 46 PHASE II CLINICAL TRIALS 2010–2020
EXHIBIT 47 CLINICAL TRIALS IN PHASE II BY THERAPEUTIC AREA (2010-2015-2020)
EXHIBIT 48 VIRTUAL EARLY STAGE CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 49 GLOBAL VIRTUAL EARLY STAGE CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 50 INCREMENTAL GROWTH BY THERAPEUTIC AREA 2021 & 2027
EXHIBIT 51 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY INDICATION 2021–2027
EXHIBIT 52 VIRTUAL THERAPEUTIC AREA CLINICAL TRIALS MARKET: INCREMENTAL GROWTH
EXHIBIT 53 VIRTUAL THERAPEUTIC AREA CLINICAL TRIALS MARKET: ABSOLUTE GROWTH
EXHIBIT 54 USED CASES OF VIRTUAL CLINICAL TRIALS IN ONCOLOGY
EXHIBIT 55 GLOBAL ONCOLOGY CLINICAL TRIALS BY PHASES (2010–2020)
EXHIBIT 56 VIRTUAL ONCOLOGY CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 GLOBAL VIRTUAL ONCOLOGY CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 58 VIRTUAL CLINICAL TRIAL ACTIVITIES BY RARE DISEASES INDICATION 2021
EXHIBIT 59 VIRTUAL RARE & GENETIC DISEASE CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 60 GLOBAL VIRTUAL RARE & GENETIC DISEASES CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 61 NEUROLOGICAL DISORDERS: GLOBAL PREVALENCE 2019–2021
EXHIBIT 62 VIRTUAL CNS CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 63 GLOBAL VIRTUAL CNS CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 64 ADOPTION OF DCT FOR IMMUNOLOGY THERAPEUTIC AREA (BEFORE & AFTER 12 MONTHS OF 2021)
EXHIBIT 65 VIRTUAL IMMUNOLOGY CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL VIRTUAL IMMUNOLOGY CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 67 RESPIRATORY DISORDER PREVALENCE 2020
EXHIBIT 68 INFECTIOUS DISEASES & PATIENT POPULATION
EXHIBIT 69 GASTROENTEROLOGY CLINICAL TRIALS BY REGION 2010–2020
EXHIBIT 70 MUSCULOSKELETAL DISORDERS BY CONDITION & PREVALENCE 2021
EXHIBIT 71 VIRTUAL CLINICAL TRIALS MARKET BY OTHER THERAPEUTIC AREAS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 72 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY OTHER THERAPEUTIC AREAS 2021–2027 ($ MILLION)
EXHIBIT 73 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
EXHIBIT 74 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY COMPANY SIZE 2021–2027
EXHIBIT 75 VIRTUAL CLINICAL TRIALS MARKET BY COMPANY SIZE: INCREMENTAL GROWTH
EXHIBIT 76 VIRTUAL CLINICAL TRIALS MARKET BY COMPANY SIZE: ABSOLUTE GROWTH
EXHIBIT 77 SMALL PHARMA/ BIOTECH COMPANIES WITH ACTIVE PIPELINE 2010–2019
EXHIBIT 78 CONTRIBUTION OF SMALL PHARMA/BIOTECH COMPANIES TO NEW FDA DRUG APPROVALS
EXHIBIT 79 NEW FDA NEW APPROVALS BY DIFFERENT COMPANY SIZES 2016–2020
EXHIBIT 80 VIRTUAL SMALL- & MID-SIZED CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 81 GLOBAL VIRTUAL SMALL- & MID-SIZED COMPANIES CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 82 LARGE PHARMACEUTICAL COMPANIES: TOTAL FDA DRUGS APPROVALS 2016–2020
EXHIBIT 83 VIRTUAL LARGE-SIZED CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 84 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY LARGE-SIZED COMPANIES 2021–2027 ($ MILLION)
EXHIBIT 85 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 86 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY REGION 2021-2027
EXHIBIT 87 ONGOING/PLANNED VIRTUAL CLINICAL TRIALS BY REGION 2020
EXHIBIT 88 VIRTUAL CLINICAL TRIALS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 89 VIRTUAL CLINICAL TRIALS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 90 NORTH AMERICA CLINICAL TRIALS 2000–2021
EXHIBIT 91 NORTH AMERICA VIRTUAL CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 92 NORTH AMERICA VIRTUAL CLINICAL TRIALS MARKET: KEY COUNTRIES
EXHIBIT 93 NORTH AMERICA VIRTUAL CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 94 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 95 POTENTIAL FACTORS DRIVING VIRTUAL CLINICAL TRIALS IN US
EXHIBIT 96 US VIRTUAL CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 97 VIRTUAL CLINICAL TRIALS MARKET IN CANADA 2021–2027 ($ MILLION)
EXHIBIT 98 EUROPE VIRTUAL CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 99 EUROPE VIRTUAL CLINICAL TRIALS MARKET: KEY COUNTRIES
EXHIBIT 100 EUROPE VIRTUAL CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 101 EUROPE VIRTUAL CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 102 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 103 CLINICAL TRIALS: FUNDING & SOURCES IN UK
EXHIBIT 104 VIRTUAL CLINICAL TRIALS MARKET IN UK 2021–2027 ($ MILLION)
EXHIBIT 105 VIRTUAL CLINICAL TRIALS MARKET IN FRANCE 2021–2027 ($ MILLION)
EXHIBIT 106 INDUSTRY-SPONSORED CLINICAL TRIALS BY TOP THERAPEUTIC AREAS IN GERMANY
EXHIBIT 107 VIRTUAL CLINICAL TRIALS MARKET IN GERMANY 2021–2027 ($ MILLION)
EXHIBIT 108 VIRTUAL CLINICAL TRIALS MARKET IN SPAIN 2021–2027 ($ MILLION)
EXHIBIT 109 VIRTUAL CLINICAL TRIALS MARKET IN ITALY 2021–2027 ($ MILLION)
EXHIBIT 110 APAC CLINICAL TRIAL LANDSCAPE 2022
EXHIBIT 111 APAC VIRTUAL CLINICAL TRIALS MARKET: KEY COUNTRIES
EXHIBIT 112 APAC VIRTUAL CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 113 APAC VIRTUAL CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 114 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 115 VIRTUAL CLINICAL TRIALS MARKET IN AUSTRALIA 2021–2027 ($ MILLION)
EXHIBIT 116 ACCEPTANCE OF VIRTUAL CLINICAL TRIAL MODEL 2020
EXHIBIT 117 ACCEPTANCE OF EIGHT COMPONENTS OF VIRTUAL CLINICAL TRIALS
EXHIBIT 118 VIRTUAL CLINICAL TRIALS MARKET IN CHINA 2021–2027 ($ MILLION)
EXHIBIT 119 VIRTUAL CLINICAL TRIALS MARKET IN SOUTH KOREA 2021–2027 ($ MILLION)
EXHIBIT 120 CHALLENGES OVERCOME WITH VIRTUAL CLINICAL TRIALS IN JAPAN
EXHIBIT 121 VIRTUAL CLINICAL TRIALS MARKET IN JAPAN 2021–2027 ($ MILLION)
EXHIBIT 122 TRIALS CONDUCTED IN INDIA CONTAINING VIRTUAL COMPONENTS
EXHIBIT 123 VIRTUAL CLINICAL TRIALS MARKET IN INDIA 2021–2027 ($ MILLION)
EXHIBIT 124 LATIN AMERICA VIRTUAL CLINICAL TRIALS MARKET: KEY COUNTRIES
EXHIBIT 125 LATIN AMERICA VIRTUAL CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 126 LATIN AMERICA VIRTUAL CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 127 LATIN AMERICA VIRTUAL CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 128 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 129 FACTORS BOOSTING CLINICAL TRIALS IN BRAZIL
EXHIBIT 130 VIRTUAL CLINICAL TRIALS MARKET IN BRAZIL 2021–2027 ($ MILLION)
EXHIBIT 131 VIRTUAL CLINICAL TRIALS MARKET IN MEXICO 2021–2027 ($ MILLION)
EXHIBIT 132 VIRTUAL CLINICAL TRIALS MARKET IN ARGENTINA 2021–2027 ($ MILLION)
EXHIBIT 133 TOP THERAPY AREAS OF INDUSTRY-SPONSORED CLINICAL TRIALS IN MEA
EXHIBIT 134 MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 135 MIDDLE EAST & AFRICA VIRTUAL CLINICAL TRIALS MARKET: KEY COUNTRIES
EXHIBIT 136 MIDDLE EAST & AFRICA VIRTUAL CLINICAL TRIALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 137 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021–2027
EXHIBIT 138 VIRTUAL CLINICAL TRIALS MARKET IN TURKEY 2021–2027 ($ MILLION)
EXHIBIT 139 VIRTUAL CLINICAL TRIALS MARKET IN SOUTH AFRICA 2021–2027 ($ MILLION)
EXHIBIT 140 VIRTUAL CLINICAL TRIALS MARKET IN SAUDI ARABIA 2021–2027 ($ MILLION)
EXHIBIT 141 VIRTUAL CLINICAL TRIAL PRODUCTS PEAK METRIC ASSESSMENT 2021
EXHIBIT 142 VENDORS OFFERING VIRTUAL CLINICAL TRIALS: MARKET DOMINANCE ANALYSIS
EXHIBIT 143 VENDORS OFFERING VIRTUAL CLINICAL TRIALS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 144 MEDABLE DECENTRALIZED CLINICAL TRIALS BY THERAPEUTIC AREAS
EXHIBIT 145 IQVIA: ANNUAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 146 LABORATORY CORPORATION OF AMERICA: ANNUAL REVENUE 2019–2021 (MILLION)
EXHIBIT 147 THERMO FISHER SCIENTIFIC: ANNUAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 148 THERMO FISHER SCIENTIFIC: REVENUE BY LABORATORY PRODUCTS & BIOPHARMA SERVICES SEGMENT 2019- 2021 ($ MILLION)
EXHIBIT 149 THERMO FISHER SCIENTIFIC: TOTAL REVENUE BY GEOGRAPHIES 2019–2021 ($ MILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 TOP BENEFITS OF VIRTUAL CLINICAL TRIALS (% OF RESPONDENTS INDICATING THIS AS THE MOST IMPORTANT BENEFIT)
TABLE 4 CHANGE IN PRE-PANDEMIC INTERACTIONS DUE TO DECENTRALIZATION OF CLINICAL TRIALS
TABLE 5 DASSAULT SYSTÈMES: MAJOR PRODUCT OFFERINGS
TABLE 6 MEDABLE: MAJOR PRODUCT OFFERINGS
TABLE 7 SCIENCE 37: MAJOR PRODUCT OFFERINGS
TABLE 8 THREAD: MAJOR PRODUCT OFFERINGS
TABLE 9 ACCENTURE: MAJOR PRODUCT OFFERINGS
TABLE 10 CASTOR: MAJOR PRODUCT OFFERINGS
TABLE 11 CLINICAL INK: MAJOR PRODUCT OFFERINGS
TABLE 12 CLARIO: MAJOR PRODUCT OFFERINGS
TABLE 13 DELVE HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 14 ECLINICALHEALTH: MAJOR PRODUCT OFFERINGS
TABLE 15 IQVIA: MAJOR PRODUCT OFFERINGS
TABLE 16 LABCORP DRUG DEVELOPMENT: MAJOR PRODUCT OFFERINGS
TABLE 17 OBVIOHEALTH: MAJOR PRODUCT OFFERINGS
TABLE 18 SIGNANT HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 19 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 20 ADVARRA: MAJOR PRODUCT OFFERINGS
TABLE 21 CURAVIT CLINICAL RESEARCH: MAJOR PRODUCT OFFERINGS
TABLE 22 CMIC HOLDINGS: MAJOR PRODUCT OFFERINGS
TABLE 23 ICON PLC: MAJOR PRODUCT OFFERINGS
TABLE 24 JEEVA INFORMATICS SOLUTIONS: MAJOR PRODUCT OFFERINGS
TABLE 25 LEO INNOVATION LAB: MAJOR PRODUCT OFFERINGS
TABLE 26 ORACLE: MAJOR PRODUCT OFFERINGS
TABLE 27 PARAXEL INTERNATIONAL CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 28 PROPHARMA GROUP: MAJOR PRODUCT OFFERINGS
TABLE 29 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 30 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 31 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY STUDY TYPE 2021–2027 ($ MILLION)
TABLE 32 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY STUDY TYPE 2021–2027 (%)
TABLE 33 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY PHASES 2021–2027 ($ MILLION)
TABLE 34 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY PHASES 2021–2027 (%)
TABLE 35 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY COMPANY SIZE 2021–2027 ($ MILLION)
TABLE 36 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY COMPANY SIZE 2021–2027 (%)
TABLE 37 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY THERAPEUTIC AREA 2021–2027 ($ MILLION)
TABLE 38 GLOBAL VIRTUAL CLINICAL TRIALS MARKET BY THERAPEUTIC AREA 2021–2027 (%)
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY STUDY TYPE
4.3.2 MARKET SEGMENTATION BY STAGE OF DEVELOPMENT
4.3.3 MARKET SEGMENTATION BY THERAPEUTIC AREA
4.3.4 MARKET SEGMENTATION BY COMPANY SIZE
4.3.5 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 PREMIUM INSIGHTS
6.1 OVERVIEW
7 INTRODUCTION
7.1 OVERVIEW
8 MARKET AT A GLANCE
9 MARKET OPPORTUNITIES & TRENDS
9.1 ADOPTION OF “BRING-YOUR-OWN-DEVICE” STRATEGY
9.2 CLINICAL TRIALS POWERED WITH BETTER DATA THROUGH NEW CONNECTED DEVICES
9.3 ADOPTION OF SYNTHETIC CLINICAL TRIALS
10 MARKET GROWTH ENABLERS
10.1 SPIKE IN VIRTUAL CLINICAL TRIAL ADOPTION DUE TO COVID-19
10.2 DECENTRALIZATION OF CLINICAL TRIALS
10.3 REGULATORY CHANGES IN FAVOR OF VIRTUAL CLINICAL TRIALS
11 MARKET GROWTH RESTRAINTS
11.1 CHALLENGES ASSOCIATED WITH VIRTUAL CLINICAL TRIALS
11.2 COMPLEXITY IN DECENTRALIZED CLINICAL TRIALS
11.3 INCREASING ALTERNATIVES FOR VIRTUAL CLINICAL TRIALS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.2.1 INSIGHTS BY STUDY TYPE
12.2.2 INSIGHTS BY PHASES
12.2.3 INSIGHTS BY THERAPEUTIC AREA
12.2.4 INSIGHTS BY GEOGRAPHY
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY
13 STUDY DESIGN
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 INTERVENTIONAL
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 OTHERS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
14 PHASES
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 LATE STAGE
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 EARLY STAGE
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
15 THERAPEUTIC AREA
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 ONCOLOGY
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.4 RARE & GENETIC DISEASES
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.5 CENTRAL NERVOUS SYSTEM
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.6 IMMUNOLOGY
15.6.1 MARKET OVERVIEW
15.6.2 MARKET SIZE & FORECAST
15.7 OTHERS
15.7.1 MARKET OVERVIEW
15.7.2 MARKET SIZE & FORECAST
16 COMPANY SIZE
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 SMALL- & MID-SIZED
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.4 LARGE-SIZED
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
17 GEOGRAPHY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 GEOGRAPHIC OVERVIEW
18 NORTH AMERICA
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 KEY COUNTRIES
18.3.1 US: MARKET SIZE & FORECAST
18.3.2 CANADA: MARKET SIZE & FORECAST
19 EUROPE
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.3 KEY COUNTRIES
19.3.1 UK: MARKET SIZE & FORECAST
19.3.2 FRANCE: MARKET SIZE & FORECAST
19.3.3 GERMANY: MARKET SIZE & FORECAST
19.3.4 SPAIN: MARKET SIZE & FORECAST
19.3.5 ITALY: MARKET SIZE & FORECAST
20 APAC
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.3 KEY COUNTRIES
20.3.1 AUSTRALIA: MARKET SIZE & FORECAST
20.3.2 CHINA: MARKET SIZE & FORECAST
20.3.3 SOUTH KOREA: MARKET SIZE & FORECAST
20.3.4 JAPAN: MARKET SIZE & FORECAST
20.3.5 INDIA: MARKET SIZE & FORECAST
21 LATIN AMERICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.3 KEY COUNTRIES
21.3.1 BRAZIL: MARKET SIZE & FORECAST
21.3.2 MEXICO: MARKET SIZE & FORECAST
21.3.3 ARGENTINA: MARKET SIZE & FORECAST
22 MIDDLE EAST & AFRICA
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.3 KEY COUNTRIES
22.3.1 TURKEY: MARKET SIZE & FORECAST
22.3.2 SOUTH AFRICA: MARKET SIZE & FORECAST
22.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST
23 COMPETITIVE LANDSCAPE
23.1 COMPETITION OVERVIEW
23.2 MARKET SHARE ANALYSIS
23.2.1 DASSAULT SYSTÈMES
23.2.2 MEDABLE
23.2.3 SCIENCE 37
23.2.4 THREAD
24 KEY COMPANY PROFILES
24.1 DASSAULT SYSTÈMES
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.1.3 KEY STRATEGIES
24.1.4 KEY STRENGTHS
24.1.5 KEY OPPORTUNITIES
24.2 MEDABLE
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.2.3 KEY STRATEGIES
24.2.4 KEY STRENGTHS
24.2.5 KEY OPPORTUNITIES
24.3 SCIENCE 37
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.3.3 KEY STRATEGIES
24.3.4 KEY STRENGTHS
24.3.5 KEY OPPORTUNITIES
24.4 THREAD
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.4.3 KEY STRATEGIES
24.4.4 KEY STRENGTHS
24.4.5 KEY OPPORTUNITIES
25 KEY COMPANIES TO WATCH
25.1 ACCENTURE
25.1.1 BUSINESS OVERVIEW
25.1.2 PRODUCT OFFERING
25.1.3 KEY STRATEGIES
25.1.4 KEY STRENGTHS
25.1.5 KEY OPPORTUNITIES
25.2 CASTOR
25.2.1 BUSINESS OVERVIEW
25.2.2 PRODUCT OFFERINGS
25.2.3 KEY STRATEGIES
25.2.4 KEY STRENGTHS
25.2.5 KEY OPPORTUNITIES
25.3 CLINICAL INK
25.3.1 BUSINESS OVERVIEW
25.3.2 PRODUCT OFFERINGS
25.3.3 KEY STRATEGIES
25.3.4 KEY STRENGTHS
25.3.5 KEY OPPORTUNITIES
25.4 CLARIO
25.4.1 BUSINESS OVERVIEW
25.4.2 PRODUCT OFFERINGS
25.4.3 KEY STRATEGIES
25.4.4 KEY STRENGTHS
25.4.5 KEY OPPORTUNITIES
25.5 DELVE HEALTH
25.5.1 BUSINESS OVERVIEW
25.5.2 PRODUCT OFFERINGS
25.5.3 KEY STRATEGIES
25.5.4 KEY STRENGTHS
25.5.5 KEY OPPORTUNITIES
25.6 ECLINICALHEALTH (CLINPAL)
25.6.1 BUSINESS OVERVIEW
25.6.2 PRODUCT OFFERING
25.6.3 KEY STRATEGIES
25.6.4 KEY STRENGTHS
25.6.5 KEY OPPORTUNITIES
25.7 IQVIA
25.7.1 BUSINESS OVERVIEW
25.7.2 PRODUCT OFFERINGS
25.7.3 KEY STRATEGIES
25.7.4 KEY STRENGTHS
25.7.5 KEY OPPORTUNITIES
25.8 LABCORP DRUG DEVELOPMENT
25.8.1 BUSINESS OVERVIEW
25.8.2 PRODUCT OFFERINGS
25.8.3 KEY STRATEGIES
25.8.4 KEY STRENGTHS
25.8.5 KEY OPPORTUNITIES
25.9 OBVIOHEALTH
25.9.1 BUSINESS OVERVIEW
25.9.2 PRODUCT OFFERINGS
25.9.3 KEY STRATEGIES
25.9.4 KEY STRENGTHS
25.9.5 KEY OPPORTUNITIES
25.10 SIGNANT HEALTH
25.10.1 BUSINESS OVERVIEW
25.10.2 PRODUCT OFFERING
25.10.3 KEY STRATEGIES
25.10.4 KEY STRENGTHS
25.10.5 KEY OPPORTUNITIES
25.11 THERMO FISHER SCIENTIFIC
25.11.1 BUSINESS OVERVIEW
25.11.2 PRODUCT OFFERINGS
25.11.3 KEY STRATEGIES
25.11.4 KEY STRENGTHS
25.11.5 KEY OPPORTUNITIES
26 OTHER PROMINENT VENDORS
26.1 ADVARRA
26.1.1 BUSINESS OVERVIEW
26.1.2 PRODUCTS OFFERING
26.2 CURAVIT CLINICAL RESEARCH
26.2.1 BUSINESS OVERVIEW
26.2.2 PRODUCT OFFERINGS
26.3 CMIC HOLDINGS
26.3.1 BUSINESS OVERVIEW
26.3.2 PRODUCT OFFERING
26.4 ICON PLC
26.4.1 BUSINESS OVERVIEW
26.4.2 PRODUCT OFFERING
26.5 JEEVA INFORMATICS SOLUTIONS
26.5.1 BUSINESS OVERVIEW
26.5.2 PRODUCT OFFERINGS
26.6 LEO INNOVATION LAB
26.6.1 BUSINESS OVERVIEW
26.6.2 PRODUCT OFFERINGS
26.7 ORACLE
26.7.1 BUSINESS OVERVIEW
26.7.2 PRODUCT OFFERINGS
26.8 PARAXEL INTERNATIONAL CORPORATION
26.8.1 BUSINESS OVERVIEW
26.8.2 PRODUCT OFFERINGS
26.9 PROPHARMA GROUP
26.9.1 BUSINESS OVERVIEW
26.9.2 PRODUCTS OFFERING
27 REPORT SUMMARY
27.1 KEY TAKEAWAYS
27.2 STRATEGIC RECOMMENDATIONS
28 QUANTITATIVE SUMMARY
28.1 MARKET BY GEOGRAPHY
28.2 MARKET BY STUDY TYPE
28.3 MARKET BY PHASES
28.4 MARKET BY COMPANY SIZE
28.5 MARKET BY THERAPEUTIC AREA
29 APPENDIX
29.1 ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
What is the size of the global virtual clinical trials market?
What is the global virtual clinical trials market growth?
What are the trends in the global virtual clinical trials market?
Who are the key players in the global virtual clinical trials market?
Which region will dominate the global virtual clinical trials market share?
other RELATED Reports
Regulatory Affairs Outsourcing Market - Global Outlook and Forecast 2022-2027
Published : June 2022
Clinical Trials Software Market - Global Outlook and Forecast 2022-2027
Published : September 2022
Clinical Trials Outsourcing Market - Global Outlook & Forecast 2022-2027
Published : August 2022
Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027
Published : September 2022